2-(3,5-二氟苯基)-2-甲基丙酸 | 879904-44-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(3,5-二氟苯基)-2-甲基丙酸
• 英文名称: 2-(3,5-difluorophenyl)-2-methyl-propanoic acid
• 英文别名: 2-(3,5-Difluorophenyl)-2-methylpropanoic acid
• CAS: 879904-44-6
• 化学式: C₁₀H₁₀F₂O₂
• 分子量: 200.185
• InChiKey: AJWWDMCHVOGPHR-UHFFFAOYSA-N

物化性质

• 沸点：
  258.3±25.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  2-(3,5-二氟苯基)-2-甲基丙酸 在 C₄₄H₃₂N₄⁽²⁺⁾*2F₆P^(1-) 、 sodium hydroxide 作用下， 以 水 、 乙腈 为溶剂， 反应 3.0h， 以64%的产率得到
  参考文献：
  名称：

  苯撑双（苯并咪唑鎓）（BBIm2 +）：专用有机光氧化还原催化剂

  摘要：

  设计，合成并证明了由亚苯基桥联的双（苯并咪唑鎓）（BBIm 2+）组成的专用光氧化还原催化剂可促进羧酸的光化学脱羧羟基化和二聚。BBIm 2+的催化活性高于单阳离子类似物的催化活性，表明BBIm 2+的去离子性质在这些脱羧反应中起关键作用。被激发的BBIm 2+的三重态-三重态吸收的衰减速率常数随着具有饱和依赖性的羧酸根阴离子浓度的增加而增加，表明光诱导的电子转移发生在由BBIm的三重态激发态组成的离子对复合物中2+ 和羧酸根阴离子。

  DOI：

  10.1039/d0sc03958f
• 作为产物：
  描述：

  2-(3,5-difluorophenyl)-2-methylpropanenitrile 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 以2.28 g的产率得到2-(3,5-二氟苯基)-2-甲基丙酸
  参考文献：
  名称：

  [EN] MrgprX2 ANTAGONISTS AND USES THEREOF
  [FR] ANTAGONISTS DE MRGPRX2 ET LEURS UTILISATIONS

  摘要：

  本公开涉及在治疗炎症性疾病，例如皮肤炎症性疾病中使用MrgprX2拮抗剂。该发明还涉及包含MrgprX2拮抗剂和药学上可接受的载体的药物组合物，用于局部或口服给药。

  公开号：

  WO2021092264A1

文献信息

• NOVEL KINASE INHIBITORS
  申请人：Burger Matthew

  公开号：US20120225062A1

  公开（公告）日：2012-09-06

  The present invention provides compounds of Formula I: and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.

  本发明提供了如下式的化合物： 以及本文进一步描述的相关化合物，以及包含这些化合物的药物组合物。该发明还提供了使用这些化合物和组合物治疗与Pim激酶活性不良水平相关的疾病的方法，包括癌症和自身免疫性疾病。
• TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS
  申请人：Burger Matthew

  公开号：US20120225061A1

  公开（公告）日：2012-09-06

  The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

  本发明提供了一种公式(I)的化合物： 如本文所述，以及药用可接受的盐、对映异构体、旋转异构体、互变异构体或外消旋混合物。还提供了使用公式I的化合物治疗由PIM激酶介导的疾病或状况的方法，以及包含这些化合物的药物组合物。
• Piperdine Compound and Process for Preparing the Same
  申请人：Miyake Tsutomu

  公开号：US20070244158A1

  公开（公告）日：2007-10-18

  The present invention is to provide a piperidine compound represented by the formula [I]: wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted benzene ring, R 1 is hydrogen atom or a substituent for amino group, R 2 is hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z is oxygen atom or —N(R 3 )—, R 3 is hydrogen atom or an optionally substituted alkyl group, R 4a and R 4b may be the same or different, and each is hydrogen atom or an optionally substituted alkyl group, or may be bonded to each other at the both ends to form an alkylene group, or a pharmaceutically acceptable salt thereof, which has an excellent tachykinin receptor antagonistic action.

  本发明提供了一种由公式[I]表示的哌啶化合物：其中，环A是可选取代的苯环，环B是可选取代的苯环，R1是氢原子或氨基取代基，R2是氢原子、可选取代的羟基、可选取代的氨基、可选取代的烷基、取代的羰基或卤原子，Z是氧原子或-N(R3)-，R3是氢原子或可选取代的烷基，R4a和R4b可以相同也可以不同，且每个都是氢原子或可选取代的烷基，或者可以在两端结合形成烷基，或其药学上可接受的盐，具有优异的Tachykinin受体拮抗作用。
• AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1581476B1

  公开（公告）日：2016-11-16
• ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS
  申请人：Linders Theodorus Maria Joannes

  公开号：US20080096869A1

  公开（公告）日：2008-04-24

  the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n represents an integer being 1 or 2; R 1 and R 2 each independently represents hydrogen C 1-4 alkyl, NR 9 R 10 , C 1-4 alkyloxy; or R 1 and R 2 taken together with the carbon atom with which they are attached form a C 3-6 cycloalkyl; and where n is 2, either R 1 or R 2 may be absent to form an unsaturated bond; R 3 represents a C 6-12 cycloalkyl, preferably selected from cylo-octanyl and cyclohexyl or R 3 represents a monovalent radical having one of the following formulae wherein said C 6-12 cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C 1-4 alkyl, C 1-4 alkyloxy, halo or hydroxy; Q represents Het 1 or Ar 2 wherein said C 3-8 cycloalkyl, Het 1 or Ar 2 are optionally substituted with one or where possible two or more substituents selected from halo, C 1-4 alkyl, C 1-4 alkyloxy, hydroxy, nitro, NR 5 R 6 , C 1-4 alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het 2 and NR 7 R 8 , and C 1-4 alkyl substituted with one or where possible two or three halo substituents, preferably trifluoromethyl; R 5 and R 6 each independently represent hydrogen, C 1-4 alkyl, or C 1-4 alkyl substituted with phenyl; R 7 and R 8 each independently represent hydrogen or C 1-4 alkyl; R 9 and R 10 each independently represent hydrogen, C 1-4 alkyl or C 1-4 alkyloxycarbonyl; L represents C 1-4 alkyl; Het 1 represents a heterocycle selected from pyridinyl, thiophenyl, or 1,3-benzodioxolyl; Het 2 represents piperidinyl, pyrrolidinyl or morpholinyl; Ar 2 represents phenyl, naphtyl or indenyl.